[
  {
    "question": "A 58-year-old woman with HIV infection is brought to the emergency department because of a 2-week history of headaches, blurred vision, and confusion. Her current medications include antiretroviral therapy and trimethoprim-sulfamethoxazole. Neurological examination shows ataxia and memory impairment. Her CD4+ T-lymphocyte count is 90/\u03bcL. Analysis of her cerebrospinal fluid analysis shows lymphocytic predominant pleocytosis, and PCR is positive for Epstein-Barr virus DNA. An MRI of the brain with contrast shows a solitary, weakly ring-enhancing lesion with well-defined borders involving the corpus callosum. What is the most likely diagnosis?",
    "answer": "Given the patient's symptoms (headaches, blurred vision, confusion, ataxia, and memory impairment) and laboratory findings (CD4+ T-lymphocyte count 90/\u03bcL), the most likely diagnosis is **Progressive Multifocal Leukoencephalopathy (PML)**.\n\nPML is a rare and serious viral disease caused by the JC virus, which is a polyomavirus that infects the brain and spinal cord. The patient's positive PCR for Epstein-Barr virus DNA in the cerebrospinal fluid (CSF) further supports this diagnosis. The MRI findings of a weakly ring-enhancing lesion with well-defined borders involving the corpus callosum are consistent with PML.\n\nPML typically presents with a gradual decline in cognitive function, including memory loss, and can lead to severe neurological deficits if left untreated. Given the patient's CD4+ T-lymphocyte count is 90/\u03bcL, which is low, and the presence of PML, we should consider a diagnosis of **Acquired Immune Deficiency Syndrome (AIDS) with PML**.\n\nThe patient's HIV infection is a risk factor for PML, and the patient's low CD4+ T-lymphocyte count further supports this diagnosis.",
    "true_answer": "The most likely diagnosis for a patient with HIV, presenting with neurological symptoms and a solitary ring-enhancing lesion, is primary cerebral lymphoma."
  },
  {
    "question": "A 25-year-old sexually active male presents to an internal medicine physician for a routine health check up after having several unprotected sexual encounters. After appropriate testing the physician discusses with the patient that he is HIV+ and must be started on anti-retroviral treatment. What medication prescribed acts on the gp41 subunit of the HIV envelope glycoprotein?",
    "answer": "The patient is HIV+ and needs to start anti-retroviral treatment. The medication prescribed is a protease inhibitor, specifically a non-nucleoside reverse transcriptase inhibitor (NNRTI). The specific medication is lamivudine (also known as 3TC).",
    "true_answer": "The medication that targets the gp41 subunit of the HIV envelope glycoprotein is enfuvirtide."
  },
  {
    "question": "A 27-year-old man presents with a 2-week history of fever, malaise, and occasional diarrhea. On physical examination, the physician notes enlarged inguinal lymph nodes. An HIV-1 detection test is positive. Laboratory studies show a CD4+ count of 650/mm3. This patient is most likely currently in what stage of HIV infection?",
    "answer": "Based on the provided information, the patient is likely in the **Active HIV-1 infection** stage.\n\nThe patient's symptoms (fever, malaise, diarrhea) and physical examination findings (enlarged inguinal lymph nodes) suggest an active infection, and the positive HIV-1 detection test confirms the diagnosis. The low CD4+ count (650/mm3) indicates that the patient is immunocompromised and is at increased risk for opportunistic infections.",
    "true_answer": "This patient is most likely currently in the stage of acute HIV infection."
  },
  {
    "question": "A 50-year-old male with HIV presents to his primary care provider complaining of persistent fevers and night sweats over the past four months. He has also experienced a productive cough. He has been poorly adherent to his HAART regimen. His past medical history also includes gout, hypertension, and diabetes mellitus. He takes allopurinol, enalapril, and metformin. His temperature is 100.9\u00b0F (38.3\u00b0C), blood pressure is 125/75 mmHg, pulse is 95/min, and respirations are 20/min. His CD4 count is 85 cell/mm^3 and a PPD is negative. A chest radiograph reveals cavitations in the left upper lobe and left lower lobe. Bronchoalveolar lavage reveals the presence of partially acid-fast gram-positive branching rods. A head CT is negative for any intracranial process. What is the mechanism of action of the most appropriate drug for managing this patient\u2019s condition?",
    "answer": "Given the patient's symptoms and test results, it appears that the patient has pulmonary tuberculosis (TB) likely due to his HIV status, as evidenced by the positive PPD and the presence of cavitations and acid-fast gram-positive branching rods in the bronchoalveolar lavage fluid. \n\nThe most appropriate drug for managing TB in an HIV-positive patient is isoniazid (INH) monotherapy, which is the standard of care for treating latent TB in HIV-infected individuals. Isoniazid is a first-line antituberculosis medication that works by inhibiting the synthesis of the mycolic acid, a critical component of the Mycobacterium tuberculosis cell wall, leading to cell death. \n\nIsoniazid is effective against all strains of M. tuberculosis and is the first-line treatment for latent TB in HIV-positive patients, according to the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC).",
    "true_answer": "The mechanism of action of the most appropriate drug to manage this patient's condition is inhibition of bacterial folic acid synthesis."
  },
  {
    "question": "A physician scientist is looking for a more efficient way to treat HIV. Patients infected with HIV mount a humoral immune response by producing antibodies against the HIV envelope proteins. These antibodies are the same antibodies detected by the ELISA and western blot assays used to diagnose the disease. The physician scientist is trying to generate a new, more potent antibody against the same HIV envelope proteins targeted by the natural humoral immune response. Of the following proteins, which is the most likely target of the antibody he is designing?",
    "answer": "The most likely target of the antibody the physician scientist is designing would be the gp120 protein. This is the envelope glycoprotein of the HIV virus, which is responsible for binding to the CD4 receptor on the surface of T-cells, marking them for destruction. This interaction is the initial step in the viral entry process into the cell.",
    "true_answer": "The most likely target of the antibody being designed for HIV envelope proteins is gp120."
  },
  {
    "question": "A 50-year-old HIV-positive male presents to the ER with a two-day history of fever and hemoptysis. Chest radiograph shows a fibrocavitary lesion in the right middle lobe. Biopsy of the afflicted area demonstrates septate hyphae that branch at acute angles. What is the most likely causal organism?",
    "answer": "Given the clinical presentation of fever and hemoptysis, along with the chest radiograph showing a fibrocavitary lesion in the right middle lobe, and the biopsy findings of septate hyphae branching at acute angles, the most likely causal organism is Candida auris.\n\nCandida auris is a rapidly evolving, multi-drug resistant fungus that is increasingly associated with healthcare-associated infections, including pneumonia and invasive disease. Its ability to form septate hyphae and branch at acute angles is particularly characteristic of this organism.\n\nWhile other fungal pathogens, such as Pneumocystis jirovecii, can also cause lung disease, the presence of septate hyphae branching at acute angles is more suggestive of C. auris. It is worth noting that C. auris is a concern in healthcare settings, particularly in patients with compromised immune systems, and requires prompt diagnosis and treatment.\n\nIt is essential to emphasize that C. auris is not a common cause of pneumonia in the general population, and its diagnosis is often delayed until the presentation of severe illness.",
    "true_answer": "The most likely causal organism for the symptoms presented is Aspergillus fumigatus."
  },
  {
    "question": "A 43-year-old man with HIV infection comes to the physician because of a 2-week history of progressive diarrhea and a 3-kg (6.6-lb) weight loss. During this period, he has had 3\u20134 episodes of watery stools daily, with multiple instances of blood in the stool. He is currently receiving antiretroviral therapy with zidovudine, lamivudine, and dolutegravir. Physical examination shows pallor and dry mucous membranes. A colonoscopy shows multiple linear ulcers. Polymerase chain reaction of a stool sample is positive for cytomegalovirus. Treatment with valganciclovir is begun. Adding this drug to his current medication regimen puts this patient at greatest risk for what specific adverse effects?",
    "answer": "The patient is at risk for pneumocystis jirovecii pneumonia (PCP) due to the CMV co-infection.",
    "true_answer": "Treatment with valganciclovir places the patient at increased risk for pancytopenia."
  },
  {
    "question": "A 28-year-old G1P0 woman at 16 weeks estimated gestational age presents for prenatal care. Routine prenatal screening tests are performed and reveal a positive HIV antibody test. The patient is extremely concerned about the possible transmission of HIV to her baby and wants to have the baby tested as soon as possible after delivery. Which of the following would be the most appropriate diagnostic test to address this patient\u2019s concern?",
    "answer": "Given the patient's situation, the most appropriate diagnostic test to address her concern about HIV transmission to her baby would be a nucleic acid amplification test (NAAT) for HIV. This test can detect the genetic material of the virus and is considered the gold standard for diagnosing HIV infection in pregnant women. It provides a high sensitivity and specificity for detecting the virus in the blood or other bodily fluids.",
    "true_answer": "The most appropriate test for early HIV diagnosis in a newborn is the polymerase chain reaction (PCR) for HIV RNA."
  },
  {
    "question": "A 32-year-old man comes to the office for a routine health maintenance examination. He admits to recently having an affair several months ago and requests STD testing. One week later, the results of a fourth-generation HIV antibody and antigen test return positive. The patient is counseled on the test result. The patient requests that his diagnosis not be disclosed to anyone, including his wife. The man's wife is also the physician's patient. What should be the most appropriate next step by the physician?",
    "answer": "The physician should:\n\n1. Inform the patient that he has HIV and that the test result is positive, but not disclose the diagnosis to his wife, as it is not a medical emergency and his wife is his patient.\n2. Explain the importance of honesty and transparency in the doctor-patient relationship, especially when it comes to sensitive information like HIV status.\n3. Offer to discuss the situation with the patient's wife and provide her with information about HIV and the risks associated with it, to help her make an informed decision about her own health and well-being.\n4. Consider referring the patient to a counselor or social worker to support the patient in addressing any underlying issues related to his behavior and its consequences.\n5. If the patient refuses to disclose the diagnosis to his wife, the physician should respect his decision and inform his wife of the situation, but also consider the potential risks and consequences of not disclosing the diagnosis, such as his wife potentially not receiving the necessary treatment and care.\n\nIt is not appropriate to:\n\n* Refuse to disclose the diagnosis to the patient's wife, as it is a medical fact and not confidential.\n* Ignore the patient's request for confidentiality and proceed with disclosure without discussing the risks and consequences with his wife.\n* Refuse to refer the patient to a counselor or social worker without discussing the patient's concerns and needs with his wife.",
    "true_answer": "The physician should report the HIV infection to the national health authorities while maintaining confidentiality per regulations."
  },
  {
    "question": "A 41-year-old woman presents with acute onset severe epigastric pain radiating to the back that began a few hours ago. She also complains of nausea and has vomited twice in the past hour. She denies any history of similar symptoms or trauma in the past. Past medical history is significant for diabetes type 2 and HIV infection diagnosed 6 months ago long-standing mild intermittent asthma, and generalized anxiety disorder. She takes metformin for her diabetes but does not remember the names of her HIV medications. She reports moderate social alcohol use. Her vital signs include temperature 37.6\u00b0C (99.6 \u00b0F), pulse 95/min, blood pressure 110/74 mm Hg, respiratory rate 12/min Her body mass index (BMI) is 21 kg/m2. Laboratory findings are significant for the following: Serum amylase: 415 U/L, Serum lipase: 520 U/L. A contrast CT of the abdomen reveals an edematous pancreas with peripancreatic fluid collection with a normal gallbladder. What is the most likely etiology of this patient\u2019s condition?",
    "answer": "Given the patient's symptoms and laboratory findings, I would approach this case with a differential diagnosis that considers the patient's underlying conditions, medication, and the acute presentation.\n\nThe patient's symptoms of severe epigastric pain radiating to the back, nausea, and vomiting, combined with the elevated serum amylase and lipase levels, suggest an acute pancreatitis. The presence of a normal gallbladder on the CT scan reduces the likelihood of gallbladder disease as a cause of pancreatitis.\n\nThe patient's history of HIV infection, diabetes, and the recent onset of severe epigastric pain and vomiting, especially in the context of her medical history, raises concerns about a possible exacerbation of her underlying conditions, such as pancreatitis or a metabolic crisis.\n\nThe patient's social history of moderate alcohol use is also a risk factor for pancreatitis.\n\nConsidering the patient's laboratory findings, the most likely etiology of this patient's condition is a pancreatic pseudocyst, which is a common complication of acute pancreatitis. A pancreatic pseudocyst can form as a result of the inflammation of the pancreas, which can lead to the collection of fluid, often referred to as a pseudocyst. This condition can cause severe pain, nausea, vomiting, and abdominal tenderness, and can be life-threatening if it becomes infected or ruptures.\n\nThe normal gallbladder on the CT scan makes a gallbladder rupture or cholecystitis less likely, and the patient's history of diabetes and HIV infection also make gallbladder disease less likely.",
    "true_answer": "It is most likely related to their HIV medication."
  },
  {
    "question": " A 28-year-old primigravid woman at 38 weeks' gestation is brought to the emergency department in active labor. She has not had regular prenatal care. She has a history of HIV infection but is not currently on antiretroviral therapy. Her previous viral load is unknown. Treatment with intravenous zidovudine is begun to reduce perinatal transmission of the virus. What biological process is most likely disrupted by this drug\u2019s action mechanism?",
    "answer": "This patient is likely experiencing preterm labor. The use of intravenous zidovudine (AZT) to reduce perinatal transmission of HIV is a treatment strategy known as antiretroviral prophylaxis (ART). The biological process most likely disrupted by this drug's action mechanism is the replication of the HIV virus.\n\nZidovudine works by inhibiting the reverse transcriptase enzyme, which is necessary for the viral replication process. By blocking this enzyme, zidovudine prevents the virus from replicating and producing new viral particles. This reduces the viral load in the mother, thereby decreasing the risk of transmission to the baby during delivery.",
    "true_answer": " Zidovudine affects elongation of viral DNA by inhibiting the viral reverse transcriptase enzyme."
  },
  {
    "question": "What is known about DNA methylation profiles in patients with latent HIV-1 or with an active infection?",
    "answer": "DNA methylation profiles in patients with latent HIV-1 or active infection can provide valuable insights into the disease process. Here's a summary of what's known:\n\n**Latent HIV-1:**\n\n* DNA methylation of the HIV-1 long terminal repeat (LTR) is associated with the latent state, where the virus is not actively replicating.\n* Methylation of specific DNA sequences, particularly the LTR, can lead to the silencing of viral gene expression.\n* Studies have identified several DNA methylation patterns associated with latent HIV-1, including the methylation of the LTR, UG1, and UG3 regions.\n* These methylation patterns can be used as biomarkers for latent HIV-1.\n\n**Active HIV-1:**\n\n* DNA methylation of the HIV-1 LTR and UG1 region is associated with active viral replication and transmission.\n* Methylation of the UG1 region has been linked to the development of drug resistance and treatment failure.\n* The methylation status of the HIV-1 LTR can also be used as a prognostic marker for disease progression and mortality in patients with HIV-1 infection.\n\n**Key takeaways:**\n\n* Both latent and active HIV-1 have distinct DNA methylation profiles that can be used to understand the disease process and monitor treatment response.\n* These methylation patterns can provide valuable insights into the mechanisms of viral replication, transmission, and disease progression.\n\n**Important note:** It's essential to consult reputable sources and consult with an expert in the field to interpret results and discuss any specific questions or concerns.",
    "true_answer": "DNA methylation is correlated with and functionally linked to HIV-1 pathogenesis and latency. In active infection, HIV-1 infection is associated with global changes in host cell DNA methylation patterns, while in latent infection, methylation of the proviral DNA, particularly in the 5\u2019 LTR promoter and intragenic regions, plays a crucial role in maintaining viral latency."
  }
]